News & analysis · 10 stories
What's moving in GLP-1 right now
Federal pricing deals, the first Medicare obesity coverage in history, an enforcement wave against telehealth compounders, and three next-generation drugs. Covered from the position this site can actually occupy: we hold a dated price dataset, so every piece connects the news to what programs currently charge — and says plainly where the answer is not yet known.
Looking for a specific program? The provider reviews assess all 37 on record and the price database holds the figures. For evergreen explainers, see the long-form guides.
Brand GLP-1s fall to about $350 on TrumpRx
Zepbound moves from over $1,080 to about $346 and Ozempic, Wegovy and Zepbound land near $350 on the federal platform. What it does to compounded pricing.
Medicare now covers weight-loss drugs, with a $50 copay
The Medicare GLP-1 Bridge runs 1 July 2026 to 31 December 2027 with a maximum $50 monthly copay — below every cash price in our database.
The FDA sent 25 warning letters to GLP-1 telehealth firms
25 letters over allegedly false or misleading compounded GLP-1 claims — the four marketing patterns cited, and how to read a program's copy now.
The FDA 503B decision: where compounded GLP-1s actually stand
The comment period closed 30 July 2026 with no final decision. What was proposed, what is misreported, and what it means for what you pay.
Novo sues Hims & Hers as GLP-1 litigation passes 3,900 cases
A manufacturer suing the telehealth layer directly, and a product-liability MDL at 3,928 cases. Two tracks, different implications.
The 'research grade' GLP-1 crackdown
Connecticut's attorney general announced an overseas platform will cease selling research-grade GLP-1s into the US. What that label actually means.
40% of commercial plans now cover a GLP-1
Commercial coverage is up from roughly 25% in 2024, 55% of large employers are taking the obesity rider, and sleep apnea and MASH open other doors.
Foundayo (orforglipron): the first oral small-molecule GLP-1
Approved April 2026 as the first oral non-peptide GLP-1 for weight management. Why a small molecule changes the economics, and the efficacy trade-off.
Retatrutide: above 28% weight loss, and not available
Positive Phase 3 topline on 21 May 2026 with over 28% weight loss — and why anything sold as compounded retatrutide is not the trial drug.
CagriSema: the semaglutide successor to watch
Roughly 23% weight loss from cagrilintide plus semaglutide, an FDA response expected in 2026, and what it does to compounded semaglutide.